CTBP2 (C-Terminal Binding Protein 2)

Drug enrichment analysis highlighted tiopronin as promising therapeutic candidate for BaP-exposed populations. This study bridges BaP carcinogenesis and LUAD pathogenesis, offering translational insights for risk assessment, early diagnosis, and targeted therapy of BaP-related LUAD.

This study is the first to reveal that the CTBP2/ZEB1/HK2 axis drives NPC progression by coupling glycolytic regulation with EMT and metastasis. These findings uncover a critical metabolic signaling cascade in NPC progression and identify promising targets for therapeutic development and warrant further investigation as potential treatments for NPC.

In colorectal carcinoma (CRC) cells, CtBP2 and G9a co-occupy the PTEN promoter, where disruption of their interface reduces H3K9me2 deposition, derepresses PTEN expression, attenuates PI3K-AKT signaling, and impairs CRC cell proliferation. Together, these findings establish a structural framework for CtBP-mediated regulation of G9a activity and highlight the CtBP1/2-G9a complex as a potential therapeutic target in colorectal cancer.

Our findings suggest that subtle regulatory variants may contribute to favorable clinical outcomes in rare long-term survivors of R/M HNSCC. Further studies are needed to identify predictive biomarkers in this unique subgroup of patients.

In addition, AML patients with MECOM overexpression through enhancer hijacking show significantly reduced CEBPA levels. Our study directly connects two major players in normal and malignant hematopoiesis, MECOM and CEBPA, and unveils how MECOM maintains self-renewal by repressing CEBPA-induced differentiation.

Gene set enrichment analysis showed enriched pathways associated with cancer-related biological processes such as DNA repair and depleted pathways related to translation, cellular metabolic process, and mitochondrial functions. This study highlights that the distinctive genetic composition of underrepresented groups influences the penetrance of pathogenic variants that could contribute to hereditary cancer risk in ways that diverge from patterns observed in more extensively researched cohorts.

Moreover, ZNF131-354aa was found to promote E-cadherin and phosphatase and tensin homolog (PTEN) expression by interacting with the intron of the C-terminal binding protein 2 (CTBP2) gene and repressing its expression. In conclusion, ZNF131-354aa acts as a tumor suppressor in GC by inhibiting CTBP2 transcription.

Experimental validation with RT-qPCR confirmed the differential expression of the candidate biomarkers (ARRB1, RPS3A, COL4A5, COL1A2 and MED10) across the three CRC stages reinforcing their potential as stage-specific biomarkers in CRC progression. These findings provide a foundation to distinguish between the CRC stages and for the development of accurate stage-specific diagnostic and prognostic biomarkers, which helps in the development of more effective therapeutic strategies for CRC.

VDAC1 inhibition enhances mitophagy in cochlear hair cells, playing a critical role in defending against oxidative stress and inflammation. Downregulation of VDAC1 may thus be considered a therapeutic strategy for preventing cochlear hair cell damage and reducing NIHL.

From the above experiments, we found that CtBP2 can regulate the Wnt/β-catenin signaling pathway through EGR1 to influence the proliferation and apoptosis of DLBCL cells. Therefore, EGR1 may be one of the key contributors involved in the regulation of Wnt/β-catenin signaling by CtBP2.

Our findings identify for the first time that CtBP2 acts as a required critical inducing factor in the CYR61-related metastatic progression of osteosarcoma, by favoring cell migration and invasiveness. Moreover, we demonstrate that while CtBP2 is a downstream transcriptional target of CYR61 signaling cascade, it occurs only under non-hypoxic conditions. The present study suggests that CtBP2 may represent a potential pivotal target for therapeutic management of metastases spreading in osteosarcoma.

BBOX1-AS1 might regulate the E-cadherin expression through CtBP2/ZEB1 transcriptional complex-mediated transcriptional repression, further affecting the activation of the Wnt/β-catenin pathway and the EMT process. Overall, our findings demonstrate that BBOX1-AS1 might act as an lncRNA associated with EMT for facilitating GCA advancement via interaction with CtBP2 to facilitate the activation of Wnt/β-catenin pathway and the EMT process, which indicated that it might function as an exploitable treatment target for GCA patients.